You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Article metrics

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

 

Online download statistics by month:

Online download statistics by month: May 2021 to August 2025

AbstractFullPdf
May 20210337111
Jun 202109122
Jul 202108225
Aug 20210907
Sep 20210689
Oct 202106429
Nov 202106020
Dec 20210665
Jan 202203916
Feb 202204017
Mar 202203610
Apr 202203221
May 202204016
Jun 202204211
Jul 20220294
Aug 202203412
Sep 202202914
Oct 202204514
Nov 20220249
Dec 20220217
Jan 202302610
Feb 20230313
Mar 2023069115
Apr 20230319
May 2023054
Jun 2023062
Jul 20230167
Aug 2023096
Sep 2023093
Oct 202301910
Nov 20230113
Dec 20230318
Jan 202403810
Feb 20240177
Mar 20240546
Apr 20240144
May 20240158
Jun 20240248
Jul 20240235
Aug 20240193
Sep 20240147
Oct 20240107
Nov 20240185
Dec 20240287
Jan 20250147
Feb 20250144
Mar 2025091
Apr 20250316
May 202501512
Jun 20250136
Jul 2025010
Aug 2025010
Total02477612